Physician profile
Tyler Brown
NPI 1770153900
$3,125.74
in general payments reported to CMS, 2019-2025
25 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.04 · 2022: $712 · 2023: $693 · 2024: $1,119 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $536.21 | 2022-2025 | Repatha, Otezla, Otezla |
| Abbvie INC. | $357.08 | 2022-2025 | |
| Novo Nordisk INC | $302.91 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $298.91 | 2022-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbott Laboratories | $246.46 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $200.11 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Radius Health, INC. | $177.82 | 2023-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $169.94 | 2022-2025 | Eliquis, Camzyos |
| Sumitomo Pharma America, INC. | $120.04 | 2023-2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $115.12 | 2022-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $105.40 | 2024-2025 | Voquezna |
| Lundbeck LLC | $62.06 | 2024-2025 | Rexulti |
| Daiichi Sankyo INC. | $58.86 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $47.86 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $42.75 | 2022-2023 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $41.57 | 2022 | |
| Pfizer INC. | $41.09 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $35.67 | 2024-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.30 | 2022-2024 | Jardiance |
| Paratek Pharmaceuticals, INC. | $28.97 | 2022-2023 | Nuzyra |
| Alexion Pharmaceuticals, INC. | $28.25 | 2024 | Ultomiris |
| Merck Sharp & Dohme LLC | $28.01 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Exact Sciences Corporation | $21.99 | 2023 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $17.32 | 2022 | |
| Medtronic, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.